Alex Friedlaender
A5057105147- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- COVID-19 and healthcare impacts
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
- BRCA gene mutations in cancer
- Pancreatic and Hepatic Oncology Research
- Immunotherapy and Immune Responses
- COVID-19 Clinical Research Studies
- Inflammatory Biomarkers in Disease Prognosis
- Bladder and Urothelial Cancer Treatments
- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- Prostate Cancer Treatment and Research
- HER2/EGFR in Cancer Research
- Multiple and Secondary Primary Cancers
- Pleural and Pulmonary Diseases
- Brain Metastases and Treatment
- Cancer Mechanisms and Therapy
- Neuroendocrine Tumor Research Advances
- Hepatocellular Carcinoma Treatment and Prognosis
- Occupational and environmental lung diseases
Générale-Beaulieu Clinic
2021-2025
University Hospital of Geneva
2018-2024
Hôpital Beau-Séjour
2018-2023
Geneva College
2021-2023
University of Geneva
2019-2021
Swiss Cancer Center Léman
2021
Centre Léon Bérard
2018
Background Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients non-small cell lung cancer (NSCLC) (according to programmed death-ligand 1 (PD-L1) expression and treatment line). Whether such relationship is causative or associative matter of debate. Methods We present the outcomes analysis according baseline (prior ICI initiation) putative immune-modulatory effects...
Abstract BRCA1/BRCA2 genes play a central role in DNA repair and their mutations increase sensitivity to DNA-damaging agents. There are conflicting data regarding the prognostic value of BRCA germline breast cancer (BC) patients. We collected clinical, pathological genetic cohort 925 BC patients preselected for screening treated with neoadjuvant or adjuvant chemotherapy, whom 266 were carriers. Overall, 171 women carried BRCA1 mutation, 95 BRCA2 659 non-carriers. In entire cohort, there was...
Background The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression. Methods We present the analysis according to baseline body mass index (BMI) BMI variation a large cohort metastatic NSCLC with expression ≥50%, first line pembrolizumab. also evaluated control treated platinum-based...
Background/Aim: KRAS mutation is the most frequent molecular alteration found in advanced non-small cell lung cancer (NSCLC). It associated with a poor prognosis without available targeted therapy. Treatment options for NSCLC have been recently enriched by development of immune checkpoint inhibitors (ICIs), and data about their efficacy patients KRAS-mutant are discordant. This study assessed routine ICIs NSCLC. Patients Methods: All stage IV treated our institution from January 2016 to...
Cases of the 2019 novel coronavirus also known as severe acute respiratory syndrome 2 (SARS-CoV-2) continue to rise worldwide. To date, there is no effective treatment. Clinical management largely symptomatic, with organ support in intensive care for critically ill patients. The first phase I trial test efficacy a vaccine has recently begun, but meantime an urgent need decrease morbidity and mortality cases. It that patients cancer are more susceptible infection than individuals without...